AlphaGrep UK’s Neurocrine Biosciences NBIX Stock Holding History

AlphaGrep UK’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,252	Closed	-$560K	–	882
2026 Q1	$560K	Buy	4,252 +91	+2%	+$12.1K	0.16%	194
2025 Q4	$590K	Buy	+4,161	New	+$603K	0.2%	157

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

AlphaGrep UK's NBIX Position: Q2 2026 in Review

AlphaGrep UK sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 4,252 shares — an estimated $560K sold.

AlphaGrep UK first reported a position in NBIX in Q4 2025 and held it in 2 quarters. The position peaked at $590K in Q4 2025. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

AlphaGrep UK reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 4,252 Neurocrine Biosciences shares in Q2 2026, an estimated $560K.
AlphaGrep UK first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 2 quarters.
AlphaGrep UK's Neurocrine Biosciences position peaked at $590K in Q4 2025.
733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.